New definition for the partial remission period in children and adolescents with type 1 diabetes

Diabetes Care

Volumn 32, Issue 8, 2009, Pages 1384-1390

  Mortensen, Henrik B ^a   Hougaard, Philip ^b   Swift, Peter ^c   Hansen, Lars ^a   Holl, Reinhard W ^d   Hoey, Hilary ^e   Bjoerndalen, Hilde ^f   De Beaufort, Carine ^g   Chiarelli, Francesco ^h   Danne, Thomas ⁱ   Schoenle, Eugen J ^j   Åman, Jan ^k  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY OF ULM   (Germany)

^e TRINITY COLLEGE DUBLIN   (Ireland)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^h Clinica Pediatrica   (Italy)

ⁱ Kinderkrankenhaus Auf der Bult ^*  (Germany)

^j UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^k ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN;

ADOLESCENT; ARTICLE; CELL FUNCTION; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DRUG EFFICACY; GLYCEMIC CONTROL; GROUPS BY AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; MAJOR CLINICAL STUDY; MATHEMATICAL VARIABLE; MULTICENTER STUDY; PANCREAS ISLET BETA CELL; PARTIAL REMISSION; PREDICTIVE VALIDITY; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; REMISSION; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; AGING; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; INSULIN; LONGITUDINAL STUDIES; MULTIVARIATE ANALYSIS; PUBERTY; REGRESSION ANALYSIS; REMISSION, SPONTANEOUS;

EID: 68149136902     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1987     Document Type: Article

References (22)

1. Buyukgebiz A, Cemeroglu AP, Bober E, Mohn A, Chiarelli F. Factors influencing remission phase in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001;14:1585-1596 (Pubitemid 34036916)
2. Akirav E, Kushner JA, Herold KC. β-Cell mass and type 1 diabetes: going, going, gone? Diabetes 2008;57:2883-2888
3. Hramiak IM, Dupre J, Finegood DT. Determinants of clinical remission in recentonset IDDM. Diabetes Care 1993;16:125-132 (Pubitemid 23013836)
4. Muhammad BJ, Swift PGF, Raymond NT, Botha JL. Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child 1999;80:367-369 (Pubitemid 29164763)
5. Kordonouri O, Danne T, Enders I, Weber B. Does the long-term clinical course of type I diabetes mellitus differ in patients with prepubertal and pubertal onset? Results of the Berlin Retinopathy Study. Eur J Pediatr 1998;157:202-207 (Pubitemid 28113873)
6. Couper J, Donaghue K. Phases of diabetes. Pediatr Diabetes 2007;8:44-47
7. Sochett EB, Daneman D, Clarson C, Ehrlich RM. Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia 1987;30:453-459 (Pubitemid 17139071)
8. Mortensen HB, Volund A. Application of a biokinetic model for prediction and assessment of glycated haemoglobins in diabetic patients. Scand J Clin Lab Invest 1988;48:595-602 (Pubitemid 18236045)
9. Scholin A, Berne C, Schvarcz E, Karlsson FA, Bjork E. Factors predicting clinical remission in adult patients with type 1 diabetes. J Intern Med 1999;245:155-162 (Pubitemid 29089112)
10. Ortqvist E, Falorni A, Scheynius A, Persson B, Lernmark A. Age governs genderdependent islet cell autoreactivity and predicts the clinical course in childhood IDDM. Acta Paediatr 1997;86:1166-1171 (Pubitemid 27509426)
11. Bonfanti R, Bognetti E, Meschi F, Brunelli A, Riva MC, Pastore MR, Calori G, Chiumello G. Residual β-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty. Acta Diabetol 1998;35:91-95 (Pubitemid 28403239)
12. Komulainen J, Lounamaa R, Knip M, Kaprio EA, Akerblom HK. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual β cell function: Childhood Diabetes in Finland Study Group. Arch Dis Child 1996;75:410-415 (Pubitemid 26405681)
13. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA Workshop, 21-22 October 2001. Diabetes 2004;53:250-264 (Pubitemid 38044724)
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
15. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Last amended with Note of Clarification on Paragraph 29 by the WMA General Assembly, Washington, 2002
16. Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries: The Hvidore Study Group on Childhood Diabetes. Diabetes Care 1997;20:714-720 (Pubitemid 27274294)
17. Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. Ann Intern Med 1998;128:517-523
18. Chase HP, MacKenzie TA, Burdick J, Fiallo-Scharer R, Walravens P, Klingensmith G, Rewers M. Redefining the clinical remission period in children with type 1 diabetes. Pediatr Diabetes 2004;5: 16-19 (Pubitemid 38489440)
19. Yki-Jarvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. N Engl J Med 1986;315:224-230 (Pubitemid 16097124)
20. Bonfanti R, Bazzigaluppi E, Calori G, Riva MC, Viscardi M, Bognetti E, Meschi F, Bosi E, Chiumello G, Bonifacio E. Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with type 1 diabetes mellitus. Diabet Med 1998;15:844-850 (Pubitemid 28451954)
21. Abdul-Rasoul M, Habib H, Al-Khouly M. 'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes 2006;7:101-107
22. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention [article online], 2008. Available from http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm071624.pdf. Accessed 3 April 2008